-
Archives
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- November 2010
- October 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
-
Meta
Category Archives: Asma
Guias Clinicas de Asma
FFuente: Servicio Vasco de Saludasma, asma, asma, asma, asma Guia de Asmahttp://www.scribd.com/embeds/70793728/content?start_page=1&view_mode=list&access_key=key-1zdwr82im1tl0qguqj27(function() { var scribd = document.createElement(“script”); scribd.type = “text/javascript”; scribd.async = true; scribd.src = “http://www.scribd.com/javascripts/embed_code/inject.js”; var s = document.getElementsByTagName(“script”)[0]; s.parentNode.insertBefore(scribd, s); })(); http://feeds.feedburner.com/MedicinaGeneralYFamiliar
Posted in Asma, guia clinica, servicio vasco de salud
Leave a comment
Asthma, placebo, and how not to kill your patients
Image via Wikipedia Source: Science Based Medicine A number of years ago I was walking along Lake Michigan with a friend (a fellow medical resident) when she turned to me and said, “are you wheezing? Do you have asthma?” I … Continue reading
Posted in Asma, asthma, Placebo
Leave a comment
Revisa la FDA retiro de fármacos contra el asma por sus efectos
■ Pide retirar tratamientos con agonistas LABA en menores de 18 años y de Serevent y Foradil en pacientes de todas las edades ■ La semana próxima consultarán a un panel de expertos Reuters Washington, 5 de diciembre. Los reguladores … Continue reading
Posted in Asma, Efectos Adversos, FDA, LABA, Medicamentos, Noticias
Leave a comment
Revisa la FDA retiro de fármacos contra el asma por sus efectos
■ Pide retirar tratamientos con agonistas LABA en menores de 18 años y de Serevent y Foradil en pacientes de todas las edades ■ La semana próxima consultarán a un panel de expertos Reuters Washington, 5 de diciembre. Los reguladores … Continue reading
Posted in Asma, Efectos Adversos, FDA, LABA, Medicamentos, Noticias
Leave a comment
Antiasmaticos en el NYT
Warning Given on Use of 4 Popular Asthma Drugs, but Debate Remains By GARDINER HARRIS Published: December 5, 2008 WASHINGTON — Two federal drug officials have concluded that asthma sufferers risk death if they continue to use four hugely popular … Continue reading
Posted in Asma, Efectos Adversos, Medicamentos, Noticias, NYT
Leave a comment
Antiasmaticos en el NYT
Warning Given on Use of 4 Popular Asthma Drugs, but Debate Remains By GARDINER HARRIS Published: December 5, 2008 WASHINGTON — Two federal drug officials have concluded that asthma sufferers risk death if they continue to use four hugely popular … Continue reading
Posted in Asma, Efectos Adversos, Medicamentos, Noticias, NYT
Leave a comment
Anticolinergicos y eventos cardiovasculares
Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Singh S, Loke YK, Furberg CD. Department of Medicine, One Medical Center Blvd, Wake Forest University School of Medicine, Winston-Salem, NC … Continue reading
Posted in anticolinergicos, Asma, JAMA, mortalidad, Riesgo Cardiovascular
Leave a comment
Anticolinergicos y eventos cardiovasculares
Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Singh S, Loke YK, Furberg CD. Department of Medicine, One Medical Center Blvd, Wake Forest University School of Medicine, Winston-Salem, NC … Continue reading
Posted in anticolinergicos, Asma, JAMA, mortalidad, Riesgo Cardiovascular
Leave a comment
Fiebre, paracetamol y riesgo de asma, rinoconjuntivitis y eczema
Association between paracetamol use in infancy and childhood, and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6–7 years: analysis from Phase Three of the ISAAC programme Prof Richard Beasley DSc a , Tadd Clayton MSc b, Prof Julian … Continue reading
Posted in Asma, eczema, Efectos Adversos, paracetamol, rinoconjuntivitis, The Lancet
Leave a comment
Fiebre, paracetamol y riesgo de asma, rinoconjuntivitis y eczema
Association between paracetamol use in infancy and childhood, and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6–7 years: analysis from Phase Three of the ISAAC programme Prof Richard Beasley DSc a , Tadd Clayton MSc b, Prof Julian … Continue reading
Posted in Asma, eczema, Efectos Adversos, paracetamol, rinoconjuntivitis, The Lancet
Leave a comment
Selective Provision of Asthma Self-Management Tools to Families
Published online April 1, 2008 PEDIATRICS Vol. 121 No. 4 April 2008, pp. e900-e905 (doi:10.1542/peds.2007-1559) This Article Full Text Full Text (PDF) P3Rs: Submit a response Alert me when this article is cited Alert me when P3Rs are posted Alert … Continue reading
Macrólidos para el asma crónica
Richeldi L, Ferrara G, Fabbri LM, Lasserson TJ, Gibson PG Éste es el resumen de una revisión Cochrane traducida. La Colaboración Cochrane prepara y actualiza estas revisiones sistemáticas. El texto completo de la revisión traducida se publica en La Biblioteca … Continue reading
Posted in Asma, Colaboracion Cochrane, Macrolidos
Tagged Asma, Cochrane, cronica, Macrolidos
Leave a comment
En las reagudizaciones del asma, el aumento de las dosis previas de corticoides inhalados no produce beneficio
Artículos relacionados en EvidPediatr PubMed sobre este tema Scholar sobre este tema Artículo en pdf Versión para imprimir Buscar: autor: claves: Búsqueda avanzada University of Michigan Department of Pediatrics Evidence-Based Pediatrics Web Site. Critically Appraised Topics (Temas Valorados Críticamente). … Continue reading
Posted in Asma, Evidencias en Pediatria, Medicamentos
Tagged Asma, corticoides, Evidencias en Pediatria, Medicamentos, pediatria, reagudizacion, Salud Infantil
1 Comment
Budesonide – Formoterol
Title Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Comments Erratum in: Eur Respir J. 2003 May;21(5):912. Authors Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H Source … Continue reading
Posted in Asma, Colaboracion Cochrane, Medicamentos, Medicina Basada en la Evidencia
Tagged Asma, Colaboracion Cochrane, Medicamentos, revision
1 Comment
En las reagudizaciones del asma, el aumento de las dosis previas de corticoides inhalados no produce beneficio
Artículos relacionados en EvidPediatr PubMed sobre este tema Scholar sobre este tema Artículo en pdf Versión para imprimir Buscar: autor: claves: Búsqueda avanzada University of Michigan Department of Pediatrics Evidence-Based Pediatrics Web Site. Critically Appraised Topics (Temas Valorados Críticamente). … Continue reading
Posted in Asma, pediatria, Salud Infantil
Tagged Asma, corticoides, pediatria, Salud Infantil, tratamiento
Leave a comment
Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children
EBM Reviews – Cochrane Database of Systematic Reviews Ducharme, FM. Di Salvio, F. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. [Systematic Review] Cochrane Airways Group Cochrane Database of Systematic … Continue reading
Posted in Asma, Colaboracion Cochrane
Tagged antileucotrienos, Asma, Cochrane, corticoides inhalados, pediatria, salud en adultos, Salud Infantil
Leave a comment
Estudio SMART: salmeterol y asma A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the SMART Study Group * From the National Jewish Medical and Research Center (Dr. Nelson), Denver, CO; Brigham and Women’s Hospital and Harvard Medical School (Dr. Weiss), Boston, MA; Wake Forest University School of Medicine (Dr. Bleecker), Winston Salem, NC; and GlaxoSmithKline (Mr. Yancey and Dr. Dorinsky), Research Triangle Park, NC.More… Correspondence to: Paul M. Dorinsky, MD, GlaxoSmithKline, 5 Moore Dr, Research Triangle Park, NC 27709; e-mail: paul.m.dorinsky@gsk.com Abstract Study objective: To compare the safety of salmeterol xinafoate or placebo added to usual asthma care. Design: A 28-week, randomized, double-blind, placebo-controlled, observational study. Setting: Study subjects were seen once in the study physician’s office for screening and were provided all blinded study medication for the entire study period. Follow-up by telephone was scheduled every 4 weeks. Participants: Subjects (> 12 years old) with asthma as judged by the study physician were eligible. Individuals with a history of long-acting ß2-agonist use were excluded. Interventions: Salmeterol, 42 µg bid via metered-dose inhaler (MDI), and placebo bid via MDI. Measurements and results: Following an interim analysis in 26,355 subjects, the study was terminated due to findings in African Americans and difficulties in enrollment. The occurrence of the primary outcome, respiratory-related deaths, or life-threatening experiences was low and not significantly different for salmeterol vs placebo (50 vs 36; relative risk [RR] = 1.40; 95% confidence interval [CI], 0.91 to 2.14). There was a small, significant increase in respiratory-related deaths (24 vs 11; RR, 2.16; 95% CI, 1.06 to 4.41) and asthma-related deaths (13 vs 3; RR, 4.37; 95% CI, 1.25 to 15.34), and in combined asthma-related deaths or life-threatening experiences (37 vs 22; RR, 1.71; 95% CI, 1.01 to 2.89) in subjects receiving salmeterol vs placebo. The imbalance occurred largely in the African-American subpopulation: respiratory-related deaths or life-threatening experiences (20 vs 5; RR, 4.10; 95% CI, 1.54 to 10.90) and combined asthma-related deaths or life-threatening experiences (19 vs 4; RR, 4.92; 95% CI, 1.68 to 14.45) in subjects receiving salmeterol vs placebo. Conclusions: For the primary end point in the total population, there were no significant differences between treatments. There were small, but statistically significant increases in respiratory-related and asthma-related deaths and combined asthma-related deaths or life-threatening experiences in the total population receiving salmeterol. Subgroup analyses suggest the risk may be greater in African Americans compared with Caucasian subjects. Whether this risk is due to factors including but not limited to a physiologic treatment effect, genetic factors, or patient behaviors leading to poor outcomes remains unknown. Estudio SMART: The Salmeterol Multicenter Asthma Research Trial
The Salmeterol Multicenter Asthma Research Trial A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the … Continue reading
Posted in Asma, Medicamentos, mortalidad, Salud Infantil
Tagged , Asma, ensayo clinico, mortalidad, salmeterol, SMART
Leave a comment
Estudio SMART: salmeterol y asma A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the SMART Study Group * From the National Jewish Medical and Research Center (Dr. Nelson), Denver, CO; Brigham and Women’s Hospital and Harvard Medical School (Dr. Weiss), Boston, MA; Wake Forest University School of Medicine (Dr. Bleecker), Winston Salem, NC; and GlaxoSmithKline (Mr. Yancey and Dr. Dorinsky), Research Triangle Park, NC.More… Correspondence to: Paul M. Dorinsky, MD, GlaxoSmithKline, 5 Moore Dr, Research Triangle Park, NC 27709; e-mail: paul.m.dorinsky@gsk.com Abstract Study objective: To compare the safety of salmeterol xinafoate or placebo added to usual asthma care. Design: A 28-week, randomized, double-blind, placebo-controlled, observational study. Setting: Study subjects were seen once in the study physician’s office for screening and were provided all blinded study medication for the entire study period. Follow-up by telephone was scheduled every 4 weeks. Participants: Subjects (> 12 years old) with asthma as judged by the study physician were eligible. Individuals with a history of long-acting ß2-agonist use were excluded. Interventions: Salmeterol, 42 µg bid via metered-dose inhaler (MDI), and placebo bid via MDI. Measurements and results: Following an interim analysis in 26,355 subjects, the study was terminated due to findings in African Americans and difficulties in enrollment. The occurrence of the primary outcome, respiratory-related deaths, or life-threatening experiences was low and not significantly different for salmeterol vs placebo (50 vs 36; relative risk [RR] = 1.40; 95% confidence interval [CI], 0.91 to 2.14). There was a small, significant increase in respiratory-related deaths (24 vs 11; RR, 2.16; 95% CI, 1.06 to 4.41) and asthma-related deaths (13 vs 3; RR, 4.37; 95% CI, 1.25 to 15.34), and in combined asthma-related deaths or life-threatening experiences (37 vs 22; RR, 1.71; 95% CI, 1.01 to 2.89) in subjects receiving salmeterol vs placebo. The imbalance occurred largely in the African-American subpopulation: respiratory-related deaths or life-threatening experiences (20 vs 5; RR, 4.10; 95% CI, 1.54 to 10.90) and combined asthma-related deaths or life-threatening experiences (19 vs 4; RR, 4.92; 95% CI, 1.68 to 14.45) in subjects receiving salmeterol vs placebo. Conclusions: For the primary end point in the total population, there were no significant differences between treatments. There were small, but statistically significant increases in respiratory-related and asthma-related deaths and combined asthma-related deaths or life-threatening experiences in the total population receiving salmeterol. Subgroup analyses suggest the risk may be greater in African Americans compared with Caucasian subjects. Whether this risk is due to factors including but not limited to a physiologic treatment effect, genetic factors, or patient behaviors leading to poor outcomes remains unknown. Estudio SMART: The Salmeterol Multicenter Asthma Research Trial
The Salmeterol Multicenter Asthma Research Trial A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the … Continue reading
Posted in Asma, Medicamentos, mortalidad, Salud Infantil
Tagged Asma, ensayo clinico, mortalidad, salmeterol, SMART
Leave a comment
Estudio SMART: opinion del Instituto Catalan de Farmacologia
El analisis de dicho estudio por el ICF puede ser visto en http://www.icf.uab.es/WebsietesDB/shortcut.asp?refid=75959
Posted in Asma, Medicamentos
Tagged , agonistas beta dos de larga accion, estudio SMART, instituto catalan de farmacologia, salmeterol
1 Comment
National Asthma Guidelines Updated
National Asthma Guidelines Updated BETHESDA, MD — September 5, 2007 — The National Asthma Education and Prevention Program (NAEPP) issued the first comprehensive update in a decade of clinical guidelines for the diagnosis and management of asthma. The guidelines emphasize … Continue reading
Posted in Asma, Guias Clinicas
Tagged , actualizacion, Asma, Guias Clinicas, NAEPP, national asthma education and prevention program
Leave a comment
Tratamientos del asma Basados en la Evidencia
“No existe ningún problema, por complicado que sea, que cuando se analiza adecuadamente, no se complique más aún”. A. Koestler Tratamientos del asma Basados en la Evidencia Dr. D. Pere Casan Clará. Departamento de Pneumología. Hospital de la Santa Creu … Continue reading
Posted in Asma, Medicina Basada en la Evidencia
Tagged , Asma, Medicina Basada en la Evidencia, MSD, tratamiento
Leave a comment
GAPURMED/GAPURJovenes
